The Readout Loud
Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what's cooler than $100 billion?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss the scandalous end of Eric Lander's tenure as presidential science adviser with STAT Washington correspondent Lev Facher and science writer Megan Molteni. Then we dive into the FDA's about-face on cancer drugs developed in China and what it means for the cost of medicine in the U.S. We also explain how Pfizer's record-setting year somehow disappointed Wall Street and explore whether it's a good idea to end mask mandates.